source
- GSK to acquire Chimagen’s trispecific T-cell engager program in deal up to $750 millionGSK announced it will acquire a preclinical trispecific T cell engager program from Chinese biotech Chimagen Biosciences in a transaction that could total up to $750 million. The agreement provide…
- Medtronic and Given Imaging recall Bravo CF esophageal pH monitoring capsule delivery devicesMedtronic and its subsidiary Given Imaging have issued a recall of the Bravo CF esophageal pH monitoring capsule delivery devices after reports that the capsules may fail to attach or detach from t…